blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1729807

EP1729807 - COMBINATION THERAPY WITH AZD-2171 [Right-click to bookmark this link]
Former [2006/50]COMBINATION THERAPY
[2009/28]
StatusNo opposition filed within time limit
Status updated on  17.09.2010
Database last updated on 16.07.2024
Most recent event   Tooltip21.09.2012Lapse of the patent in a contracting state
New state(s): LU		published on 24.10.2012  [2012/43]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2009/46]
Former [2006/50]For all designated states
AstraZeneca AB
S-151 85 Södertälje / SE
Inventor(s)01 / Wedge, Stephen Robert, AstraZeneca R & D Alderley
Alderley Park
Macclesfield Cheshire SK10 4TG / GB
 [2006/50]
Application number, filing date05729377.122.03.2005
[2006/50]
WO2005GB01089
Priority number, dateGB2004000644523.03.2004         Original published format: GB 0406445
[2006/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005092385
Date:06.10.2005
Language:EN
[2005/40]
Type: A2 Application without search report 
No.:EP1729807
Date:13.12.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 06.10.2005 takes the place of the publication of the European patent application.
[2006/50]
Type: B1 Patent specification 
No.:EP1729807
Date:11.11.2009
Language:EN
[2009/46]
Search report(s)International search report - published on:EP02.11.2006
ClassificationIPC:A61K45/06, A61K31/337, A61K31/517, A61P35/00
[2009/28]
CPC:
A61K45/06 (EP,KR,US); A61K31/337 (EP,US); A61K31/517 (EP,US);
A61P11/06 (EP); A61P15/00 (EP); A61P19/02 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P43/00 (EP); A61P9/10 (EP); A61P9/14 (EP) (-)
C-Set:
A61K31/337, A61K2300/00 (EP,US);
A61K31/517, A61K2300/00 (US,EP)
Former IPC [2006/50]A61K45/06, A61K31/337, A61K31/517
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/50]
Extension statesALNot yet paid
BANot yet paid
HR02.05.2007
LV02.05.2007
MKNot yet paid
YUNot yet paid
TitleGerman:KOMBINATIONSTHERAPIE MIT AZD-2171[2009/28]
English:COMBINATION THERAPY WITH AZD-2171[2009/28]
French:THERAPIE DE COMBINAISON AVEC AZD-2171[2009/28]
Former [2006/50]KOMBINATIONSTHERAPIE
Former [2006/50]COMBINATION THERAPY
Former [2006/50]THERAPIE DE COMBINAISON
Entry into regional phase23.10.2006National basic fee paid 
02.05.2007Designation fee(s) paid 
02.05.2007Examination fee paid 
Examination procedure02.05.2007Examination requested  [2007/24]
02.12.2008Despatch of a communication from the examining division (Time limit: M04)
22.02.2009Reply to a communication from the examining division
18.06.2009Communication of intention to grant the patent
18.09.2009Fee for grant paid
18.09.2009Fee for publishing/printing paid
Opposition(s)12.08.2010No opposition filed within time limit [2010/42]
Fees paidRenewal fee
05.03.2007Renewal fee patent year 03
10.03.2008Renewal fee patent year 04
31.03.2008Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT11.11.2009
BE11.11.2009
CY11.11.2009
CZ11.11.2009
DK11.11.2009
EE11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
RO11.11.2009
SI11.11.2009
SK11.11.2009
BG11.02.2010
GR12.02.2010
IS11.03.2010
PT11.03.2010
IE22.03.2010
LU22.03.2010
MC31.03.2010
HU12.05.2010
[2012/43]
Former [2012/42]AT11.11.2009
BE11.11.2009
CY11.11.2009
CZ11.11.2009
DK11.11.2009
EE11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
RO11.11.2009
SI11.11.2009
SK11.11.2009
BG11.02.2010
GR12.02.2010
IS11.03.2010
PT11.03.2010
IE22.03.2010
MC31.03.2010
HU12.05.2010
Former [2011/07]AT11.11.2009
BE11.11.2009
CY11.11.2009
CZ11.11.2009
DK11.11.2009
EE11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
RO11.11.2009
SI11.11.2009
SK11.11.2009
BG11.02.2010
GR12.02.2010
IS11.03.2010
PT11.03.2010
IE22.03.2010
MC31.03.2010
Former [2010/46]AT11.11.2009
BE11.11.2009
CY11.11.2009
CZ11.11.2009
DK11.11.2009
EE11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
RO11.11.2009
SI11.11.2009
SK11.11.2009
BG11.02.2010
GR12.02.2010
IS11.03.2010
PT11.03.2010
MC31.03.2010
Former [2010/39]AT11.11.2009
BE11.11.2009
CY11.11.2009
CZ11.11.2009
DK11.11.2009
EE11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
RO11.11.2009
SI11.11.2009
SK11.11.2009
BG11.02.2010
IS11.03.2010
PT11.03.2010
Former [2010/31]AT11.11.2009
BE11.11.2009
CY11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
SI11.11.2009
IS11.03.2010
PT11.03.2010
Former [2010/30]AT11.11.2009
CY11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
SI11.11.2009
IS11.03.2010
PT11.03.2010
Former [2010/25]CY11.11.2009
FI11.11.2009
LT11.11.2009
PL11.11.2009
SI11.11.2009
IS11.03.2010
PT11.03.2010
Former [2010/23]FI11.11.2009
LT11.11.2009
PL11.11.2009
SI11.11.2009
IS11.03.2010
PT11.03.2010
Former [2010/21]LT11.11.2009
IS11.03.2010
PT11.03.2010
Cited inInternational search[DI]WO0047212  (ASTRAZENECA UK LTD [GB], et al) [DI] 1-16 * page 84, line 30 - page 86, line 23; example 240 *;
 [PX]WO2004096224  (BOEHRINGER INGELHEIM INT [DE], et al) [PX] 1-16* pages 70-71 *;
 [PX]WO2005004871  (ASTRAZENECA AB [SE], et al) [PX] 11 * page 15 *;
 [A]  - MALIK A K HANS-PETER GERBER, "Targeting VEGF ligands and receptors in cancer", TARGETS, ELSEVIER, (20030401), vol. 2, no. 2, ISSN 1477-3627, pages 48 - 57, XP004886645 [A] 1-16 * page 51, column L, paragraph 3 * * page 50, column R, paragraph 2 * * page 55; table 3 * * page 49, column R, paragraph 5 *

DOI:   http://dx.doi.org/10.1016/S1477-3627(03)02292-X
 [A]  - MARME D, "THE IMPACT OF ANTI-ANGIOGENIC AGENTS ON CANCER THERAPY", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, (2003), vol. 129, no. 11, ISSN 0171-5216, pages 607 - 620, XP001182072 [A] 1-3,7-12,14-16 * page 616, column L, paragraph 2 * * page 617, column L * * page 614, column L, paragraph 2; table 3 *

DOI:   http://dx.doi.org/10.1007/s00432-003-0488-9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.